A Roadmap for Personalized Medicine: the findings of the IC2PerMed Project 

A Roadmap for Personalized Medicine: the findings of the IC2PerMed Project | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article A Roadmap for Personalized Medicine: the findings of the IC2PerMed Project Flavia Beccia, Francesco Andrea Causio, Marzia Di Marcantonio, and 12 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4643972/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Personalized medicine (PM) tailors prevention and treatment to individuals based on their unique characteristics. It can improve health outcomes and healthcare sustainability by optimizing resource allocation. The European Union (EU) and China both prioritize PM. The IC2PerMed project aims to facilitate collaboration by developing a PM roadmap. This paper presents the main project’s output, a roadmap for implementing PM in the EU and China, promoting best practice exchange, and addressing potential barriers. We assessed PM in the EU and China by mapping policies, programs, funding mechanisms, and health ecosystems. Three Delphi surveys highlighted 65 priorities, which were synthesized into actions. The study identifies priorities to unlock PM's potential for healthcare transformation and better public health. The roadmap includes structural actions, like enhancing health literacy, fostering intersectoral and international collaboration, continuously reviewing technologies, and facilitating innovation market entry through needs assessment and Health Technology Assessment. Data interoperability and shared standards are critical for creating international platforms, and ethical, social, and regulatory considerations are universal in PM processes. A shared action plan can guide health policy and help policymakers understand the interconnection between healthcare, the economy, and society. By supporting international projects and investing in research and innovation, stakeholders can advance global healthcare. Personalized medicine Roadmap China European Union Priorities Figures Figure 1 Introduction Since the completion of the Human Genome Project two decades ago, significant advances in genomic medicine and the incorporation of genomic information in diagnostic, treatment, and reimbursement practices contributed to reshaping medical practice [ 1 , 2 ]. It started the so-called genomic revolution and the field of Personalized Medicine (PM), described as tailoring prevention, diagnostic methods and therapies based on patient’s genetic and lifestyle characteristics [ 3 – 5 ]. Shifting away from the traditional "one size fits all" approach, PM offers more precise and effective treatments and better outcomes, leading to advantages for healthcare professionals and systems in terms of quality of care and sustainability [ 6 , 7 ]. The European Union (EU) issued several policies to foster the adoption of PM, such us digital innovation and interoperability, patients'/citizens' engagement and healthcare sustainability [ 8 , 9 ]. Starting in 2015 with the definition of PM, the EU recognized the potential of PM and placed it at the forefront of its research agenda, supporting projects spanning the entire value chain of PM and promoting international collaborations through the International Consortium of Personalized Medicine (ICPerMed) [ 8 , 9 ]. In the global networks, explored by specific Coordination and Support Actions funded by the EU Commission, the EU objectives in PM align with China [ 10 ], where the adoption and promotion of PM followed similar steps to the European scenario. The Chinese attention to PM is testified by its inclusion in the 13th Five-Year Plan (2016–2020) and the following 14th Five-Year Plan (2021–2024), as well as in the Healthy China 2030 initiative. The country is committed to addressing the burden of non-communicable diseases and healthcare inequalities through substantial investments in multisector collaboration and innovation, particularly in cancer, promoting health education, raising awareness, improving early diagnosis, and enhancing treatment effectiveness. In addition, these plans address disparities in economic development and healthcare access across different regions of China, providing financial support, encouraging research and development, and creating a favourable regulatory framework [ 11 , 12 ].Considering these similarities, the ICPerMed launched in 2020 the "Integrating China in the International Consortium for Personalized Medicine" (IC2PerMed) project, ultimately aiming at encouraging collaboration and integration in the network [ 8 ]. Laying its methodology foundation in the “ICPerMed Vision for 2030” [ 13 ], the IC2PerMed project supports research, funding, and implementation of innovative PM approaches, with the overarching goal of establishing a preferential exchange platform between the EU and China [ 14 ]. This comprehensive roadmap for PM implementation across both regions outlines action priorities to facilitate the exchange of best practices and address potential barriers, to deepen and promote alignment for the creation of a common ground for European and Chinese collaborations on PM. Material and methods The ICPerMed approach has been used as a guiding framework during the whole conduction of the project. The activities were organised in four phases (Fig. 1 ): Mapping: identifying Chinese and EU PM-relevant policies, programs, stakeholders, actors and standards, to consider and involve in developments, envisioning benefits for healthcare ecosystems and for populations; Expertising: building upon exchange between experts’ domains for fostering actionable approaches; Exemplifying: setting concrete practices of collaboration over a PM core theme (biobanks) for illustrating and inspiring research collaborations; Engaging: creating solid bridges with European, Chinese and global key stakeholders, integrating Chinese stakeholders in ICPerMed and liaising with international peers. The IC2PerMed Roadmap is the result of a three-step methodology: Mapping and experts’ survey Workshops and Delphi survey of experts Theme analyses and results synthesis into actions Mapping and survey of experts A literature mapping explored the current landscape of PM implementation, relevant policies, projects, initiatives, standards and regulations in the EU and China. Findings were revised and expanded through a survey of 47 experts, from EU and China, exploring the main areas of interest and the international collaborations in place [ 10 ]. The results were disseminated in scientific papers and publicly available deliverables [ 9 , 14 – 17 ]. Workshops and Delphi survey of experts As reported in the introduction section, the project’s structure followed the classification laid out in the ICPerMed Vision for 2030 [ 12 ]. The subsequent work was articulated in three pillars: Shaping sustainable healthcare Innovation and market Research and clinical studies in PM. Three working groups (WGs) were established, each addressing the challenges of one of the three pillars, respectively: Shaping sustainable healthcare , focusing on Developing awareness and empowerment of patients and citizens, education and training of healthcare professionals and healthcare sustainability; Innovation and market , focusing on Big data and Information Communications and Technology (ICT) solutions and Bringing innovation to market; Research and clinical studies in PM , focusing on Translating basic to clinical research and beyond and research funding. Each WG organized three rounds of workshops to discuss preliminary priorities, identify potential gaps in literature results and up-to-date evidence on laws and guidelines, and bring important topics left out from the mapping into the discussion. Finally, nine workshops took place [ 18 ]. The preliminary results obtained in each of the three WGs were further evaluated in three Delphi surveys, one for each main pillar of discussion. The consensus was reached after two rounds for each Delphi survey, and some priorities were identified. The detailed methodology and the resulting list of 65 priorities were reported in four position papers [ 19 – 22 ]. Theme analyses and results synthesis into IC2PerMed actions For each pillar, a theme analysis on the identified priorities was performed, using the NVivo software (version 12). The final 65 priorities, derived from the position papers, were consequently merged into IC2PerMed actions that fed our roadmap, coding them according to the sub-topic they dealt with. The results are presented qualitatively, reporting the coded sub-topics as bullet points. The study protocol was approved by the Università Cattolica del Sacro Cuore Ethical Review Board (ID5249). Results The actions of the IC2PerMed Roadmap are reported according to the three main pillars in the Table 1 . For each pillar, the actions were further grouped according to the main priorities in each WG (Table 1 ). The detailed description of each action is reported below, for each of the three pillars. Table 1 IC2PerMed Roadmap’s actions Pillar I: Shaping Sustainable Healthcare Improving empowered and responsible citizens Promoting a trained and up-to-date healthcare workforce Fostering healthcare systems' sustainability a. Health Literacy b. Research c. Public Trust d. ELSI a. Education and ethics b. Collaborations c. Policies a. Resources b. ELSI c. Evaluation d. Networks Pillar II: Innovation and market Bringing innovation to market Adopting Big Data and ICT solutions a. Cost-effectiveness b. Needs assessment c. Principles and guidelines d. Perspectives a. Data Exchange b. Privacy, security, and trust c. Standards Pillar III: Research and clinical studies in PM Fostering research funding Translating basic clinical research and beyond a. Patient needs b. Value chain c. Synergies a. Omics sciences b. Data and standards c. Collaborations Pillar 1: Shaping sustainable healthcare I-Improving empowered and responsible citizens a. Health literacy Promoting health literacy is a prerequisite for better citizens’ and patients’ engagement and empowerment. The growing significance of digital technologies and the pivotal role they play in facilitating the engagement process underscore the necessity to enhance digital literacy. Given the advancement of genomics and the widespread use of predictive genetic/genomic testing, informing citizens and patients could give them greater awareness about their health trajectories. The impact of healthcare professionals’ literacy should be considered, as they are a proxy for public engagement in the self-management of health and disease. b. Research Fostering needs-assessment research and communication activities in the field of citizens’ and patients’ education related to PM could lead to more effective empowerment of citizens and patients alike. c. Public trust Scientific research, public organisations and private institutions are key innovation actors in PM. Sustaining public trust and collaborations between different institutions nationally and internationally is the drive for healthcare transformation and public health promotion. In addition, public trust should be fostered and strengthened to protect patients’ rights through clear data governance in accordance with the Helsinki Declaration and the General Data Protection Regulation (GDPR), implementing technical solutions to safeguard cyber security, citizens and health practitioner engagement, and developing comprehensive consent procedures where needed. d. Ethical challenges A valid set of values and ethical principles should focus on the economic challenges and the inequality burden. II-Promoting a trained and up-to-date healthcare workforce e. Education and ethics Improving healthcare professionals’ literacy and expertise, valuing integrity and ethics, could help foster PM. Research aimed at identifying effective methods should be promoted. f. Collaborations The future of healthcare professionals' training relies on multidisciplinary collaborations. Fostering collaborations between professionals from different specialities and between professionals and stakeholders while establishing more partnerships among countries to facilitate sharing of best practices. g. Policies Literacy in PM among healthcare professionals is an emerging focal point in national governmental strategies, policies, and agendas. III-Fostering healthcare systems’ sustainability h. Resources A better allocation of resources on PM can foster the sustainability of health systems. In particular, the identification of a large investment stream for long-term data storage is a fundamental prerequisite for implementing PM strategies. Investment priorities for product and process innovation should be defined, considering the relationship between results and costs by identifying new payment models for public reimbursement. i. ELSI & Costs Ethical, Legal, and Social Implications (ELSI) and associated expenses must consistently factor into policy formation, assessment, and the governance of technological advancements in PM. j. Evaluation Health technologies are evolving rapidly and the translation of new discoveries underpins innovation and quality of care. Therefore, a system of continuous assessment of technologies and processes already in use and a change of perspective in Health Technology Assessment (HTA) is needed to integrate end-user perceptions into the innovation process. This would ensure greater effectiveness and usability. k. Networks Multidisciplinary and cross-sectoral collaborations for PM can promote the sustainability of health systems. Public-private partnerships and international networks should be valued for sharing experiences and promoting and evaluating best practices and progress in PM. Pillar 2: Innovation and market I- Bringing innovation to market a. Cost-effectiveness The application of personalized diagnostics and therapeutics should be geared towards lowering economic costs and barriers to market uptake. Regarding diagnostics, promoting research in PM aimed at more appropriate use of diagnostic tools (avoiding overuse, overdiagnosis and overtreatment) could lead to optimal use of resources in the field of prevention and, consequently, an increase in the value of healthcare. Health insurance providers should extend their coverage to innovative and high-value PM solutions, and reimbursement of services should be promoted or attempts should be made to reduce barriers to reimbursement. In implementation processes, economic, cost-effectiveness, and relative value analyses should consider both social and health budgets and non-optimal resource use in the system. b. Needs assessment Considering the epidemiological scenario, new solutions on the market must emphasize maximizing health outcomes for patients. Early, intensive, coordinated and continuous dialogue among all PM stakeholders is needed to foster process optimization and accelerate the acquisition of new technologies and tools. c. Principles and guidelines The PM actors should follow shared principles and universal data sharing and exchange guidelines. Innovations that aim for higher therapeutic value should be rewarded. Social value assessment should be systematically applied. d. Perspectives Stakeholders stimulating innovation should take a holistic and long-term perspective on the balance sheet. The interconnection and mutual dependence between diagnostic and therapeutic innovations and the potential for inappropriate use/ overuse must be taken into account. II-Adopting Big Data and ICT solutions a. Data exchange To promote PM, Big Data must be analysable, comparable and interoperable across borders. The need emerges to carefully identify the type of information to be retained, increasingly favouring those related to health outcomes rather than information with no proven clinical or management value. To facilitate data exchange procedures, greater cooperation between academia, healthcare systems (including providers and payers), and industry would be advisable. b. Privacy, security, and trust Data security measures are a priority in developing new ICT solutions, which are crucial at the global level and not only focusing on high-income countries. Social and cultural differences between Europe and China should also be considered when it comes to public trust in government and state authorities, trying to reach a common understanding of shared challenges within PM. Involving the public can enhance awareness about data sharing benefits, its extended purposes, anonymization, privacy risks, security, private sector involvement, personal data protection, and foster frameworks aligned with societal agreement. c. Standards In the PM field, it is essential to study solutions aimed at effectively combining data from different sources (genetics, clinical data) and regions, focusing on their standardization for effective usage. Standards for data use should be adopted and implemented, also with a view to establishing common policies and global efforts for cross-border data sharing. Pillar 3: Research and clinical studies in PM I-Fostering research funding a. Patient needs Funding agencies should tailor investments to the needs of patients. There is a need to promote the voice of patients (and caregivers) at all stages of PM research, from co-designing research projects to advisory roles and enhancing educational initiatives to improve the scientific literacy of patients and researchers. Defining unmet needs and potential incremental innovation could help in laying the groundwork for new international collaborations. b. Value chain Investments, playing an important role in the entire value chain, are needed from basic science to implementing PM in healthcare. Funders, both public and private, act as the first filter on the prioritization of resource allocation which should be done responsibly. Furthermore, adequate investments are crucial in the research translation system. c. Synergies Establishing synergies between funders and the research community is the first step in implementing PM as a community. Implementing the exchange of researchers through mobility funding programs could promote collaboration and knowledge sharing between different countries and foster data sharing. Collaborations between funders should be established to align on research themes and fund larger, bold, cutting-edge projects that enable risk sharing. II-Translating basic clinical research and beyond d. Omics sciences Omics sciences are fundamental to the development of PM. Phenotyping patients, following defined standards, could identify similar patients. Besides genomics, applications of different omics sciences and technologies should be promoted and used to identify biomarkers suitable for PM. Innovative methods that have shown great promise in the PM field, including induced pluripotent stem cell and organ-on-chips models, should be evaluated and adopted, valuing international partnerships. e. Data and standards Standardizing approaches, including controlled access models for data sharing and clinical trials, may facilitate their implementation and help in patient stratification. Patient stratification in non-genetic/complex diseases would benefit from research programs on machine learning algorithms. Furthermore, using specific use cases could help in the development of common international standards and tools for research. Exchanges and dialogue between regulatory agencies should be promoted to overcome regulatory problems in PM, particularly on benefit-risk relationships. f. Collaborations It is important to support non-profit foundations and funding agencies to promote international collaborations, especially in oncological care and rare diseases. Establishing specific funding programmes and operational frameworks for public-private collaboration can facilitate academic and industrial access to biological samples and data for research purposes. It is necessary to facilitate and strengthen the dialogue with regulatory and HTA agencies, companies, and academic entities to gain a clear vision regarding outcomes researched and identify the most appropriate research methods to investigate PM, ensuring patient safety and adapting to the characteristics of study populations. Discussion The IC2PerMed roadmap illustrates strategic actions aimed at fostering international collaboration between China and the EU in the PM realm. These actions are intended to facilitate collaborative initiatives and enhance the optimization of research and developments, using the three pillars feeding the working groups’ activities as cornerstones. Closer cooperation between the two sides can lead to synergies and gains for both. The alignment of research efforts and promotion of common research initiatives in science and technology could lead to reduction of redundancies and improved use of available monetary, technological and human resources. Generating substantial evidence can often be challenging due to limited data availability. This is particularly frequent for patients affected by some conditions, or undergoing personalized interventions, that might not generate enough data. Partnerships between institutions working in the same field can facilitate the collation of available evidence by pooling available data. On the other hand, collaborations between diverse entities can lead to reciprocal benefits, e.g. feedback on data reproducibility to basic research institutions while enabling translational institutions to gain insights and preliminary findings from closer collaborations. In this context, clusters that bring together different entities and foster cross-field cooperation play a crucial role in facilitating such joint efforts. The current high fragmentation of the sector calls for concerted efforts towards integration under common guidelines. Engaging with all stakeholders is essential to incorporate diverse perspectives and ensure effective policy development. The IC2PerMed roadmap could orientate the efforts of policymakers, industry, healthcare professionals and citizens. Policymakers often struggle to keep up with innovation, especially in high-transformative fields like PM. Policymakers play a central role as the primary recipients of countries' assistance and research priorities, wielding significant influence in the formulation and implementation of healthcare policies. The regulatory landscape is heterogeneous and fragmented in the EU and China, often relying on ad-hoc initiatives and projects [ 9 ]. The speed at which innovation proceeds is often incompatible with the times of policymaking, leaving much room for the introduction of unregulated technologies into practice, sometimes with negative effects [ 9 ]. In healthcare, normative gaps can expose people’s health and well-being to unanticipated risks. Therefore, emerging technologies and processes should be carefully evaluated before they are adopted [ 23 ]. Significant issues can arise, possibly related to the unintended effects of adopting some technology or concerning the data generated by it. If not stored safely and anonymously, data leakages or hacker attacks can lead to data theft, with several unwanted consequences that are particularly negative in the case of genomic data [ 24 ]. Facilitating the exchange of health data among different institutions, even from different countries, is a priority in the EU, that is working for the creation of the European Health Data Space to address health-specific challenges to electronic health data access and sharing, focusing on interoperability and cross-border sharing. More federated data infrastructures (as fostered by the 1 + Million Genomes Initiative, which has led to the Beyond 1 + Million Genomes and the Genomic Data Infrastructure projects) will also contribute to this goal [ 25 – 29 ]. Big Data raises several issues, including personal data ownership and protection, skill gaps in labour markets and an emerging new digital divide [ 30 ]. Hence, policies in this field are fundamental for regulating these aspects [ 30 ]. Regarding data protection, notable distinctions exist between Europe and China. Europe’s regulation on data, the General Data Protection Regulation (GDPR), places significant emphasis on obtaining explicit consent or relying on legal exemptions for utilizing health data. In cross-border collaborations with third countries, such as China, data transfers necessitate adherence to the same level of data protection as enforced in the EU [ 31 ]. Conversely, China has implemented a comprehensive data protection framework, encompassing laws such as the Data Security Law, Cybersecurity Law, and Personal Information Protection Law [ 32 ]. These regulations are primarily oriented toward national security, public interest, and safeguarding fundamental data. Moreover, China has specific regulations, such as the Measures for Managing Scientific Data, governing the transfer of scientific data to designated data centres. These measures ensure the confidentiality and security of data, with a particular focus on prohibiting the disclosure of sensitive information [ 33 – 35 ]. The contrasting approaches between the two parts in data protection stem from their respective regulatory frameworks, varying consent requirements, and targeted legislation addressing different aspects of data protection and governance and promoting partnerships to facilitate data sharing and the creation of collaborative datasets [ 27 , 36 ]. However, new solutions and advanced technologies, even if promising better outcomes for patients, can come at a high cost, hindering the implementation process and healthcare systems’ sustainability [ 37 , 38 ]. Some solutions have been proposed, from checklists and instruments to measure PM solutions’ utility to performing economic evaluations that would ensure an intervention’s cost-effectiveness, like HTA and Health Impact Assessment (HIA) [ 39 , 40 ]. Nonetheless, need-assessment and integration of end-users’ perspectives seem to be neglected. For PM to reach its impact on patients’ health and well-being, translation of discoveries and communication across the continuum of research is required [ 41 ]. The development of preclinical and clinical model of disease benefits from the integration of ‘-omics’ data, useful to define molecular profiles. [ 42 ]. In order to standardize the process, identify biomarkers and correctly collect data, international consensus should be reached [ 42 ]. Developing new clinical trial designs including these innovative instruments and approaches contribute to the outcome research and the evaluation of interventions [ 42 ]. Cross-sectional research and collaboration should be supported by suitable funding mechanisms, valuing the existing instruments or promoting the establishment of new ones [ 43 ]. As per the mapping of major funding agencies and stakeholders in Europe and China in IC2PerMed’s deliverable D1.2, great similarities can be found in the structure of funding mechanisms and areas of interest [ 44 ]. Concerning industry and universities, which are the main actors in PM research and innovation in the EU and China [ 17 ], the results refer to the importance of investments of translating research into the market and partnerships between industrial partners and academia. Collaborations hold large economic potential, where global leaders can extend their reach and value chains to new markets. Both parties should pursue partnerships, collaborations and workshops to communicate and interact. Nonetheless, bridging the translational gap is crucial, and ensuring that universities and industries communicate will help address issues such as the skills mismatch [ 45 , 46 ]. To implement PM in clinical and public health practice, both patients and health professionals should be aware of the possibilities offered and how to make the most of them [ 6 , 19 ]. Given the need for informed, empowered, engaged and responsible citizens, there is a need to deepen digital literacy, knowledge of health data, public trust in institutions and easily accessible, reliable and understandable sources of medical information. Informed, accountable and empowered health service providers are also essential. Establish a normative framework for the exploitation of health information and research results in PM should be implemented for clinical practices [ 47 ]. Multidisciplinary collaborations improve the involvement of citizens in decision-making, promoting the creation of advocacy groups to represent the needs and perspectives of citizens and patients with policymakers [ 47 ]. Patients/citizens advocacy groups should collaborate with healthcare professionals and policymakers to improve health literacy and involvement in research, as well as to identify citizens' needs and sources of lack of trust [ 48 ]. It should be noted that the bilateral efforts on standardization in PM will benefit the whole field and allow health challenges to be tackled globally in a concerted manner. The results of this work should be considered in light of some strengths and limitations. To the authors’ knowledge, this is the first attempt to present a comprehensive roadmap addressing multiple issues in the field of PM, with a specific focus on the collaboration with China. This document offers a tool for policymakers, highlighting emerging issues and experts’ considerations in the field. In addition, this roadmap includes other relevant stakeholders in the field of PM, adding value to its content. The methodology used, particularly careful to intertwine the scientific literature, institutional sources and the opinion of experts, led to building a roadmap where each step was carefully evaluated and validated. This helped guarantee the quality and reliability of the results. In addition, the roadmap provides indications on aspects of PM that want to be as comprehensive as possible of the current scenario and challenges. However, arising from the international comparison of two realities, the European and the Chinese, which do not completely overlap in culture, political strategies, health systems, and technological advancement, it is possible that some aspects sound less specific compared to others. Furthermore, it is possible that some aspects relevant to PM have been neglected because of the adoption of as “perspectives” identified in the ICPerMed Vision for 2030. Conclusion PM has the potential to disrupt the medical field bringing major improvements for the benefit of public health. In doing so, PM affects citizens, patients, their families, and communities, at all levels of the entire healthcare system. The development of PM requires concise action across universities, industrial partners, and national governments and urges for synchronous development on a global scale. To do so, the alignment of European and Chinese efforts, finding common ground across cultural, social, and language barriers can enhance public health efforts in applying PM strategies internationally. Although different countries may have different perspectives because the specific national agenda may differ, PM acts as a collector of converging interests by acknowledging the best care for citizens and patients at its centre. The IC2PerMed roadmap represents an instrument for PM implementation, tackling the modern challenges of medicine and healthcare pragmatically in a list of doable actions. Implementing PM in a transversal way and welcoming new discoveries while considering sustainability holds the potential to have a revolutionary impact on healthcare, but this will require a concerted effort. Declarations Ethics Approval Statement: This study does not involve human participants and ethical approval was not required. Availability of data and materials: Not applicable Conflict of Interest statement: None to declare. Contributore: Sara Farina 1 , Cosimo Savoia 1 , Tommaso Osti 1 , Benoit Masquin 4 , Svetlana Klessova 4 , Timo Strohäker 6 , Giuditta Magnifico 7 , Stefano Benvenuti 7 , Andrea Wutte 8 , Bettina Borisch 9 , Maria Mata 9 Author Contributions: FB, FAC and MDM were major contributors to the drafting of the manuscript. All the other authors made important contributions and suggestions. WR and SB revised the manuscript substantially. All authors read and approved the final manuscript. Fundings: This work was supported by the European Union’s Horizon 2020 research and innovation programme [grant numbers 87469]; the National Key R&D Program of Ministry of Science and Technology of the People's Republic of China (MOST) [grant number 2021YFE019240]. The authors wish to express their sincere gratitude to all the experts who took part in the project for their valuable contributions to this study. References O’Donnell JC. Personalized medicine and the role of health economics and outcomes research: issues, applications, emerging trends, and future research. Value Health J Int Soc Pharmacoeconomics Outcomes Res 2013; 16: S1-3. Collins F. Has the revolution arrived? Nature 2010; 464: 674–675. Fosse V, Oldoni E, Bietrix F, et al. Recommendations for robust and reproducible preclinical research in personalised medicine. BMC Med 2023; 21: 14. Traversi D, Pulliero A, Izzotti A, et al. Precision Medicine and Public Health: New Challenges for Effective and Sustainable Health. J Pers Med 2021; 11: 135. Personalised medicine, https://research-and-innovation.ec.europa.eu/research-area/health/personalised-medicine_en (2023, accessed 24 July 2023). Stenzinger A, Moltzen EK, Winkler E, et al. Implementation of precision medicine in healthcare - a European perspective. J Intern Med . Epub ahead of print 16 July 2023. DOI: 10.1111/joim.13698 . Tinetti ME, Fried T. The end of the disease era. Am J Med 2004; 116: 179–185. Morsella A, Cadeddu C, Castagna C, et al. ‘Integrating China in the International Consortium for Personalized Medicine’: The Coordination and Support Action to Foster Collaboration in Personalized Medicine Development between Europe and China. Public Health Genomics 2021; 24: 310–314. Beccia F, Hoxhaj I, Castagna C, et al. An overview of Personalized Medicine landscape and policies in the European Union. Eur J Public Health 2022; 32: 844–851. Hoxhaj I, Beccia F, Morsella A, et al. A survey of experts on personalized medicine landscape in European Union and China. BMC Health Serv Res 2023; 23: 517. 中共中央 国务院印发《“健康中国2030”规划纲要》_中央有关文件_中国政府网, https://www.gov.cn/zhengce/2016-10/25/content_5124174.htm (accessed 24 July 2023). 中华人民共和国国民经济和社会发展第十四个五年规划和2035年远景目标纲要_滚动新闻_中国政府网, https://www.gov.cn/xinwen/2021-03/13/content_5592681.htm (accessed 24 July 2023). Vicente AM, Ballensiefen W, Jönsson J-I. How personalised medicine will transform healthcare by 2030: the ICPerMed vision. J Transl Med 2020; 18: 180. IC2PERMED: Fostering collaboration between Europe and China to enhance personalised medicine. Open Access Government, https://www.openaccessgovernment.org/article/ic2permed-europe-china-to-enhance-personalised-medicine/160981/ (2023, accessed 24 July 2023). Publications & public deliverables – IC2PerMed, https://www.ic2permed.eu/publications-public-deliverables-2/ (accessed 17 March 2023). Causio FA, Hoxhaj I, Beccia F, et al. Big data and ICT solutions in the European Union and in China: A comparative analysis of policies in personalized medicine. Digit Health 2022; 8: 20552076221129060. Causio FA, Hoxhaj I, Beccia F, et al. Research and innovation in personalized medicine: a descriptive synthesis of actors in the EU and China. Pers Med . Epub ahead of print 17 May 2023. DOI: 10.2217/pme-2023-0003 . Romain. Project news. IC2PerMed , https://www.ic2permed.eu/news/ (accessed 11 October 2023). Beccia F, Causio FA, Hoxhaj I, et al. Integrating China in the international consortium for personalised medicine. a position paper on healthcare professionals’ education and citizens’ empowerment in personalised medicine. BMC Med Educ 2023; 23: 438. Integrating China in the International Consortium for Personalised Medicine. A Position Paper on Research, Clinical Studies and Funding Systems in Personalised Medicine. Integrating China in the International Consortium for Personalised Medicine. A Position Paper on Innovation and Digitalization in Personalised Medicine. Integrating China in the International Consortium for Personalised Medicine. A position Paper on Personalised Medicine in Sustainable Healthcare. Callier S, Fullerton SM. Diversity and Inclusion in Unregulated mHealth Research: Addressing the Risks. J Law Med Ethics J Am Soc Law Med Ethics 2020; 48: 115–121. Oestreich M, Chen D, Schultze JL, et al. Privacy considerations for sharing genomics data. EXCLI J 2021; 20: 1243–1260. European Genomic Data Infrastructure (GDI) project, https://gdi.onemilliongenomes.eu/ (accessed 24 July 2023). Beyond One Million Genomes (B1MG) project, https://b1mg-project.eu/ (accessed 24 July 2023). EU AI Act: first regulation on artificial intelligence | News | European Parliament, https://www.europarl.europa.eu/news/en/headlines/society/20230601STO93804/eu-ai-act-first-regulation-on-artificial-intelligence (2023, accessed 24 July 2023). Minssen T, Vayena E, Cohen IG. The Challenges for Regulating Medical Use of ChatGPT and Other Large Language Models. JAMA . Epub ahead of print 6 July 2023. DOI: 10.1001/jama.2023.9651 . European Health Data Space, https://health.ec.europa.eu/ehealth-digital-health-and-care/european-health-data-space_en (2023, accessed 25 July 2023). Pastorino R, De Vito C, Migliara G, et al. Benefits and challenges of Big Data in healthcare: an overview of the European initiatives. Eur J Public Health 2019; 29: 23–27. What is GDPR, the EU’s new data protection law? GDPR.eu , https://gdpr.eu/what-is-gdpr / (2018, accessed 24 July 2023). Translation: Cybersecurity Law of the People’s Republic of China (Effective June 1, 2017). DigiChina , https://digichina.stanford.edu/work/translation-cybersecurity-law-of-the-peoples-republic-of-china-effective-june-1-2017/ (accessed 24 July 2023). Zhang L, Wang H, Li Q, et al. Big data and medical research in China. BMJ 2018; 360: j5910. Zhang L, Downs RR, Li J, et al. A Review of Open Research Data Policies and Practices in China. 2021; 20: 3. Huang Y, Cox AM, Sbaffi L. Research data management policy and practice in Chinese university libraries. J Assoc Inf Sci Technol 2021; 72: 493–506. Trottet C, Vogels T, Keitel K, et al. Modular Clinical Decision Support Networks (MoDN)-Updatable, interpretable, and portable predictions for evolving clinical environments. PLOS Digit Health 2023; 2: e0000108. Jönsson B, Hofmarcher T, Lindgren P, et al. The cost and burden of cancer in the European Union 1995–2014. Eur J Cancer Oxf Engl 1990 2016; 66: 162–170. Pastorino R, Loreti C, Giovannini S, et al. Challenges of Prevention for a Sustainable Personalized Medicine. J Pers Med 2021; 11: 311. van Rooij T, Wilson DM, Marsh S. Personalized medicine policy challenges: measuring clinical utility at point of care. Expert Rev Pharmacoecon Outcomes Res 2012; 12: 289–295. Ferrusi IL, Leighl NB, Kulin NA, et al. Do economic evaluations of targeted therapy provide support for decision makers? Am J Manag Care 2011; 17 Suppl 5 Developing: SP61-70. Equils O, Bakaj A, Wilson-Mifsud B, et al. Restoring Trust: The Need for Precision Medicine in Infectious Diseases, Public Health and Vaccines. Hum Vaccines Immunother 2023; 19: 2234787. Moutinho S. Clinical trials assess a precision-medicine approach to cancer screening. Nat Med 2023; 29: 1587–1590. Romagnuolo I, Mariut C, Mazzoni A, et al. Sino-European science and technology collaboration on personalized medicine: overview, trends and future perspectives. Pers Med 2021; 18: 455–470. Strohaeker T. D1.2 Map of major funding agencies and stakeholders in Europe and China. Peng J, Deng C. Research on the relationship between college students’ employability and IT skills training based on mixed research methods. Front Psychol 2022; 13: 1054134. Cooke J, Ariss S, Smith C, et al. On-going collaborative priority-setting for research activity: a method of capacity building to reduce the research-practice translational gap. Health Res Policy Syst 2015; 13: 25. Rasooly A, Ben-Sheleg E, Davidovitch N, et al. Rethinking the path from evidence to decision-making. Isr J Health Policy Res 2023; 12: 10. Neubeck L, Galbraith M, Drossart I, et al. The essential role of patients in advocacy and policy. Eur Heart J 2023; 44: 2506–2507. Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4643972","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":332605562,"identity":"78607be5-4a76-416b-af77-fa8f219a6f88","order_by":0,"name":"Flavia Beccia","email":"","orcid":"","institution":"Section of Hygiene, University Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Rome","correspondingAuthor":false,"prefix":"","firstName":"Flavia","middleName":"","lastName":"Beccia","suffix":""},{"id":332605564,"identity":"905374cc-8238-4736-966c-45623a3f05ad","order_by":1,"name":"Francesco Andrea Causio","email":"","orcid":"","institution":"Section of Hygiene, University Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Rome","correspondingAuthor":false,"prefix":"","firstName":"Francesco","middleName":"Andrea","lastName":"Causio","suffix":""},{"id":332605566,"identity":"a9828030-8478-4e20-9278-484b64cd1605","order_by":2,"name":"Marzia Di Marcantonio","email":"data:image/png;base64,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","orcid":"","institution":"Faculty of Economics, Università Cattolica del Sacro Cuore, Rome","correspondingAuthor":true,"prefix":"","firstName":"Marzia","middleName":"Di","lastName":"Marcantonio","suffix":""},{"id":332605568,"identity":"b51279da-ab62-4c97-a04b-6ca849b0a1c4","order_by":3,"name":"Ilda Hoxhaj","email":"","orcid":"","institution":"University of Padua","correspondingAuthor":false,"prefix":"","firstName":"Ilda","middleName":"","lastName":"Hoxhaj","suffix":""},{"id":332605569,"identity":"c7522663-e0f9-47ed-9359-ac404e990ee7","order_by":4,"name":"Chiara Cadeddu","email":"","orcid":"","institution":"Erasmus University Rotterdam","correspondingAuthor":false,"prefix":"","firstName":"Chiara","middleName":"","lastName":"Cadeddu","suffix":""},{"id":332605570,"identity":"ed78023f-598d-4e69-92ac-914ff3a3eab5","order_by":5,"name":"Melissa Campagno","email":"","orcid":"","institution":"G.A.C. Group - Innovation \u0026 Performance for Impact","correspondingAuthor":false,"prefix":"","firstName":"Melissa","middleName":"","lastName":"Campagno","suffix":""},{"id":332605571,"identity":"cf1103c1-ee01-44ea-8ba8-ed01cf56119b","order_by":6,"name":"Lena Schleicher","email":"","orcid":"","institution":"Steinbeis Foundation","correspondingAuthor":false,"prefix":"","firstName":"Lena","middleName":"","lastName":"Schleicher","suffix":""},{"id":332605572,"identity":"1be550f4-1968-44ac-af81-7ff26079a04b","order_by":7,"name":"Carmen Fotino","email":"","orcid":"","institution":"Telethon Foundation","correspondingAuthor":false,"prefix":"","firstName":"Carmen","middleName":"","lastName":"Fotino","suffix":""},{"id":332605573,"identity":"cc268ce1-1356-4b9e-bb7e-58a47a62a5bf","order_by":8,"name":"Maike Tauchert","email":"","orcid":"","institution":"Biobanking and Biomolecular Resources Research Infrastructure - ERIC","correspondingAuthor":false,"prefix":"","firstName":"Maike","middleName":"","lastName":"Tauchert","suffix":""},{"id":332605574,"identity":"a90b8ff3-99d3-4e3d-b498-132515a27ad1","order_by":9,"name":"Marta Lomazzi","email":"","orcid":"","institution":"World Federation of Public Health Associations","correspondingAuthor":false,"prefix":"","firstName":"Marta","middleName":"","lastName":"Lomazzi","suffix":""},{"id":332605575,"identity":"1241fbe0-a9db-4df1-acc8-4549ac83623f","order_by":10,"name":"Lili Wang","email":"","orcid":"","institution":"Jingyi Alliance Clinical Application; BGI","correspondingAuthor":false,"prefix":"","firstName":"Lili","middleName":"","lastName":"Wang","suffix":""},{"id":332605576,"identity":"f566f2c0-4e84-435b-b69b-b86a786d775d","order_by":11,"name":"Wenya Wang","email":"","orcid":"","institution":"Tsinghua University","correspondingAuthor":false,"prefix":"","firstName":"Wenya","middleName":"","lastName":"Wang","suffix":""},{"id":332605577,"identity":"daa23d72-a0a9-4c85-8737-4a779899f98b","order_by":12,"name":"Huiyao Huang","email":"","orcid":"","institution":"Academic Director, Clinical Trials Center of National Cancer Center","correspondingAuthor":false,"prefix":"","firstName":"Huiyao","middleName":"","lastName":"Huang","suffix":""},{"id":332605578,"identity":"d0eaf7eb-2a8c-4e09-b798-dff69e964737","order_by":13,"name":"Walter Ricciardi","email":"","orcid":"","institution":"Section of Hygiene, University Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Rome","correspondingAuthor":false,"prefix":"","firstName":"Walter","middleName":"","lastName":"Ricciardi","suffix":""},{"id":332605579,"identity":"6e35edbb-2e57-43b8-b707-1fe41bc49ff1","order_by":14,"name":"Stefania Boccia","email":"","orcid":"","institution":"Section of Hygiene, University Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Rome","correspondingAuthor":false,"prefix":"","firstName":"Stefania","middleName":"","lastName":"Boccia","suffix":""}],"badges":[],"createdAt":"2024-06-26 16:11:47","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4643972/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4643972/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":62125194,"identity":"d81593c8-158c-4fe6-be4a-6f189100ebee","added_by":"auto","created_at":"2024-08-09 14:34:02","extension":"jpeg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":277935,"visible":true,"origin":"","legend":"\u003cp\u003eMethodology synthesis: how actions of IC2PerMed Roadmap were derived\u003c/p\u003e","description":"","filename":"floatimage1.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-4643972/v1/a1a63df6d9b9660cae3b81a3.jpeg"},{"id":77820547,"identity":"693d227d-b2ac-4d6e-898b-fcd5f8c2ccf0","added_by":"auto","created_at":"2025-03-05 20:08:40","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":844891,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4643972/v1/95223d61-ce9b-41b3-bfd3-d40adad56084.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"A Roadmap for Personalized Medicine: the findings of the IC2PerMed Project ","fulltext":[{"header":"Introduction","content":"\u003cp\u003eSince the completion of the Human Genome Project two decades ago, significant advances in genomic medicine and the incorporation of genomic information in diagnostic, treatment, and reimbursement practices contributed to reshaping medical practice [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. It started the so-called genomic revolution and the field of Personalized Medicine (PM), described as tailoring prevention, diagnostic methods and therapies based on patient\u0026rsquo;s genetic and lifestyle characteristics [\u003cspan additionalcitationids=\"CR4\" citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]. Shifting away from the traditional \"one size fits all\" approach, PM offers more precise and effective treatments and better outcomes, leading to advantages for healthcare professionals and systems in terms of quality of care and sustainability [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. The European Union (EU) issued several policies to foster the adoption of PM, such us digital innovation and interoperability, patients'/citizens' engagement and healthcare sustainability [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]. Starting in 2015 with the definition of PM, the EU recognized the potential of PM and placed it at the forefront of its research agenda, supporting projects spanning the entire value chain of PM and promoting international collaborations through the International Consortium of Personalized Medicine (ICPerMed) [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eIn the global networks, explored by specific Coordination and Support Actions funded by the EU Commission, the EU objectives in PM align with China [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e], where the adoption and promotion of PM followed similar steps to the European scenario.\u003c/p\u003e \u003cp\u003eThe Chinese attention to PM is testified by its inclusion in the 13th Five-Year Plan (2016\u0026ndash;2020) and the following 14th Five-Year Plan (2021\u0026ndash;2024), as well as in the Healthy China 2030 initiative. The country is committed to addressing the burden of non-communicable diseases and healthcare inequalities through substantial investments in multisector collaboration and innovation, particularly in cancer, promoting health education, raising awareness, improving early diagnosis, and enhancing treatment effectiveness. In addition, these plans address disparities in economic development and healthcare access across different regions of China, providing financial support, encouraging research and development, and creating a favourable regulatory framework [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e].Considering these similarities, the ICPerMed launched in 2020 the \"Integrating China in the International Consortium for Personalized Medicine\" (IC2PerMed) project, ultimately aiming at encouraging collaboration and integration in the network [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]. Laying its methodology foundation in the \u0026ldquo;ICPerMed Vision for 2030\u0026rdquo; [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e], the IC2PerMed project supports research, funding, and implementation of innovative PM approaches, with the overarching goal of establishing a preferential exchange platform between the EU and China [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e]. This comprehensive roadmap for PM implementation across both regions outlines action priorities to facilitate the exchange of best practices and address potential barriers, to deepen and promote alignment for the creation of a common ground for European and Chinese collaborations on PM.\u003c/p\u003e"},{"header":"Material and methods","content":"\u003cp\u003eThe ICPerMed approach has been used as a guiding framework during the whole conduction of the project. The activities were organised in four phases (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e):\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003col\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003eMapping: identifying Chinese and EU PM-relevant policies, programs, stakeholders, actors and standards, to consider and involve in developments, envisioning benefits for healthcare ecosystems and for populations;\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003eExpertising: building upon exchange between experts\u0026rsquo; domains for fostering actionable approaches;\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003eExemplifying: setting concrete practices of collaboration over a PM core theme (biobanks) for illustrating and inspiring research collaborations;\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003cspan\u003e \u003cli\u003e \u003cp\u003eEngaging: creating solid bridges with European, Chinese and global key stakeholders, integrating Chinese stakeholders in ICPerMed and liaising with international peers.\u003c/p\u003e \u003c/li\u003e \u003c/span\u003e \u003c/ol\u003e \u003c/p\u003e \u003cp\u003eThe IC2PerMed Roadmap is the result of a three-step methodology:\u003c/p\u003e \u003cp\u003e \u003cul\u003e \u003cli\u003e \u003cp\u003eMapping and experts\u0026rsquo; survey\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eWorkshops and Delphi survey of experts\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eTheme analyses and results synthesis into actions\u003c/p\u003e \u003c/li\u003e \u003c/ul\u003e \u003c/p\u003e \u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eMapping and survey of experts\u003c/h2\u003e \u003cp\u003eA literature mapping explored the current landscape of PM implementation, relevant policies, projects, initiatives, standards and regulations in the EU and China. Findings were revised and expanded through a survey of 47 experts, from EU and China, exploring the main areas of interest and the international collaborations in place [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]. The results were disseminated in scientific papers and publicly available deliverables [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan additionalcitationids=\"CR15 CR16\" citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e].\u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003eWorkshops and Delphi survey of experts\u003c/h3\u003e\n\u003cp\u003eAs reported in the \u003cspan refid=\"Sec1\" class=\"InternalRef\"\u003eintroduction\u003c/span\u003e section, the project\u0026rsquo;s structure followed the classification laid out in the ICPerMed Vision for 2030 [\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]. The subsequent work was articulated in three pillars:\u003c/p\u003e \u003cp\u003e \u003cul\u003e \u003cli\u003e \u003cp\u003eShaping sustainable healthcare\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eInnovation and market\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eResearch and clinical studies in PM.\u003c/p\u003e \u003c/li\u003e \u003c/ul\u003e \u003c/p\u003e \u003cp\u003eThree working groups (WGs) were established, each addressing the challenges of one of the three pillars, respectively:\u003c/p\u003e \u003cp\u003e \u003cul\u003e \u003cli\u003e \u003cp\u003e \u003cem\u003eShaping sustainable healthcare\u003c/em\u003e, focusing on Developing awareness and empowerment of patients and citizens, education and training of healthcare professionals and healthcare sustainability;\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003e \u003cem\u003eInnovation and market\u003c/em\u003e, focusing on Big data and Information Communications and Technology (ICT) solutions and Bringing innovation to market;\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003e \u003cem\u003eResearch and clinical studies in PM\u003c/em\u003e, focusing on Translating basic to clinical research and beyond and research funding.\u003c/p\u003e \u003c/li\u003e \u003c/ul\u003e \u003c/p\u003e \u003cp\u003eEach WG organized three rounds of workshops to discuss preliminary priorities, identify potential gaps in literature results and up-to-date evidence on laws and guidelines, and bring important topics left out from the mapping into the discussion. Finally, nine workshops took place [\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThe preliminary results obtained in each of the three WGs were further evaluated in three Delphi surveys, one for each main pillar of discussion. The consensus was reached after two rounds for each Delphi survey, and some priorities were identified.\u003c/p\u003e \u003cp\u003eThe detailed methodology and the resulting list of 65 priorities were reported in four position papers [\u003cspan additionalcitationids=\"CR20 CR21\" citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e].\u003c/p\u003e\n\u003ch3\u003eTheme analyses and results synthesis into IC2PerMed actions\u003c/h3\u003e\n\u003cp\u003eFor each pillar, a theme analysis on the identified priorities was performed, using the NVivo software (version 12). The final 65 priorities, derived from the position papers, were consequently merged into IC2PerMed actions that fed our roadmap, coding them according to the sub-topic they dealt with.\u003c/p\u003e \u003cp\u003eThe results are presented qualitatively, reporting the coded sub-topics as bullet points.\u003c/p\u003e \u003cp\u003eThe study protocol was approved by the Universit\u0026agrave; Cattolica del Sacro Cuore Ethical Review Board (ID5249).\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003eThe actions of the IC2PerMed Roadmap are reported according to the three main pillars in the Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e. For each pillar, the actions were further grouped according to the main priorities in each WG (Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e). The detailed description of each action is reported below, for each of the three pillars.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eIC2PerMed Roadmap\u0026rsquo;s actions\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"4\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colspan=\"4\" nameend=\"c4\" namest=\"c1\"\u003e \u003cp\u003ePillar I: Shaping Sustainable Healthcare\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eImproving empowered and responsible citizens\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e\u003cem\u003ePromoting a trained and up-to-date healthcare workforce\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u003cem\u003eFostering healthcare systems' sustainability\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ea. Health Literacy\u003c/p\u003e \u003cp\u003eb. Research\u003c/p\u003e \u003cp\u003ec. Public Trust\u003c/p\u003e \u003cp\u003ed. ELSI\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003ea. Education and ethics\u003c/p\u003e \u003cp\u003eb. Collaborations\u003c/p\u003e \u003cp\u003ec. Policies\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003ea. Resources\u003c/p\u003e \u003cp\u003eb. ELSI\u003c/p\u003e \u003cp\u003ec. Evaluation\u003c/p\u003e \u003cp\u003ed. Networks\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"4\" nameend=\"c4\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePillar II: Innovation and market\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003e\u003cem\u003eBringing innovation to market\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e\u003cem\u003eAdopting Big Data and ICT solutions\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003ea. Cost-effectiveness\u003c/p\u003e \u003cp\u003eb. Needs assessment\u003c/p\u003e \u003cp\u003ec. Principles and guidelines\u003c/p\u003e \u003cp\u003ed. Perspectives\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003ea. Data Exchange\u003c/p\u003e \u003cp\u003eb. Privacy, security, and trust\u003c/p\u003e \u003cp\u003ec. Standards\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"4\" nameend=\"c4\" namest=\"c1\"\u003e \u003cp\u003e\u003cb\u003ePillar III: Research and clinical studies in PM\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003e\u003cem\u003eFostering research funding\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e\u003cem\u003eTranslating basic clinical research and beyond\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003ea. Patient needs\u003c/p\u003e \u003cp\u003eb. Value chain\u003c/p\u003e \u003cp\u003ec. Synergies\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003ea. Omics sciences\u003c/p\u003e \u003cp\u003eb. Data and standards\u003c/p\u003e \u003cp\u003ec. Collaborations\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e\u003cbr\u003e\u003cp\u003e\u003cu\u003ePillar 1: Shaping sustainable healthcare\u003c/u\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eI-Improving empowered and responsible citizens\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003ea.\u0026nbsp; \u0026nbsp; \u0026nbsp;Health literacy\u003c/p\u003e\n\u003cp\u003ePromoting health literacy is a prerequisite for better citizens\u0026rsquo; and patients\u0026rsquo; engagement and empowerment. The growing significance of digital technologies and the pivotal role they play in facilitating the engagement process underscore the necessity to enhance digital literacy. Given the advancement of genomics and the widespread use of predictive genetic/genomic testing, informing citizens and patients could give them greater awareness about their health trajectories. The impact of healthcare professionals\u0026rsquo; literacy should be considered, as they are a proxy for public engagement in the self-management of health and disease.\u003c/p\u003e\n\u003cp\u003eb.\u0026nbsp; \u0026nbsp; \u0026nbsp;Research\u003c/p\u003e\n\u003cp\u003eFostering needs-assessment research and communication activities in the field of citizens\u0026rsquo; and patients\u0026rsquo; education related to PM could lead to more effective empowerment of citizens and patients alike.\u003c/p\u003e\n\u003cp\u003ec.\u0026nbsp; \u0026nbsp; \u0026nbsp;Public trust\u003c/p\u003e\n\u003cp\u003eScientific research, public organisations and private institutions are key innovation actors in PM. Sustaining public trust and collaborations between different institutions nationally and internationally is the drive for healthcare transformation and public health promotion. In addition, public trust should be fostered and strengthened to protect patients\u0026rsquo; rights through clear data governance in accordance with the Helsinki Declaration and the General Data Protection Regulation (GDPR), implementing technical solutions to safeguard cyber security, citizens and health practitioner engagement, and developing comprehensive consent procedures where needed.\u003c/p\u003e\n\u003cp\u003ed.\u0026nbsp; \u0026nbsp; \u0026nbsp;Ethical challenges\u003c/p\u003e\n\u003cp\u003eA valid set of values and ethical principles should focus on the economic challenges and the inequality burden.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eII-Promoting a trained and up-to-date healthcare workforce\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003ee.\u0026nbsp; \u0026nbsp; \u0026nbsp;Education and ethics\u003c/p\u003e\n\u003cp\u003eImproving healthcare professionals\u0026rsquo; literacy and expertise, valuing integrity and ethics, could help foster PM. Research aimed at identifying effective methods should be promoted.\u003c/p\u003e\n\u003cp\u003ef.\u0026nbsp; \u0026nbsp; \u0026nbsp;Collaborations\u003c/p\u003e\n\u003cp\u003eThe future of healthcare professionals\u0026apos; training relies on multidisciplinary collaborations. Fostering collaborations between professionals from different specialities and between professionals and stakeholders while establishing more partnerships among countries to facilitate sharing of best practices.\u003c/p\u003e\n\u003cp\u003eg. \u0026nbsp; \u0026nbsp; Policies\u003c/p\u003e\n\u003cp\u003eLiteracy in PM among healthcare professionals is an emerging focal point in national governmental strategies, policies, and agendas.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eIII-Fostering healthcare systems\u0026rsquo; sustainability \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003cbr\u003e\u0026nbsp;\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eh.\u0026nbsp; \u0026nbsp; \u0026nbsp;Resources\u003c/p\u003e\n\u003cp\u003eA better allocation of resources on PM can foster the sustainability of health systems. In particular, the identification of a large investment stream for long-term data storage is a fundamental prerequisite for implementing PM strategies. Investment priorities for product and process innovation should be defined, considering the relationship between results and costs by identifying new payment models for public reimbursement.\u003c/p\u003e\n\u003cp\u003ei.\u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;ELSI \u0026amp; Costs\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eEthical, Legal, and Social Implications (ELSI) and associated expenses must consistently factor into policy formation, assessment, and the governance of technological advancements in PM.\u003c/p\u003e\n\u003cp\u003ej.\u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;Evaluation\u003c/p\u003e\n\u003cp\u003eHealth technologies are evolving rapidly and the translation of new discoveries underpins innovation and quality of care. Therefore, a system of continuous assessment of technologies and processes already in use and a change of perspective in Health Technology Assessment (HTA) is needed to integrate end-user perceptions into the innovation process. This would ensure greater effectiveness and usability.\u003c/p\u003e\n\u003cp\u003ek.\u0026nbsp; \u0026nbsp; \u0026nbsp;Networks\u003c/p\u003e\n\u003cp\u003eMultidisciplinary and cross-sectoral collaborations for PM can promote the sustainability of health systems. Public-private partnerships and international networks should be valued for sharing experiences and promoting and evaluating best practices and progress in PM.\u003c/p\u003e\n\u003cp\u003e\u003cbr\u003e\u003cu\u003ePillar 2: Innovation and market\u003c/u\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eI- Bringing innovation to market\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003ea.\u0026nbsp; \u0026nbsp; \u0026nbsp;Cost-effectiveness\u003c/p\u003e\n\u003cp\u003eThe application of personalized diagnostics and therapeutics should be geared towards lowering economic costs and barriers to market uptake. Regarding diagnostics, promoting research in PM aimed at more appropriate use of diagnostic tools (avoiding overuse, overdiagnosis and overtreatment) could lead to optimal use of resources in the field of prevention and, consequently, an increase in the value of healthcare. Health insurance providers should extend their coverage to innovative and high-value PM solutions, and reimbursement of services should be promoted or attempts should be made to reduce barriers to reimbursement. In implementation processes, economic, cost-effectiveness, and relative value analyses should consider both social and health budgets and non-optimal resource use in the system.\u003c/p\u003e\n\u003cp\u003eb.\u0026nbsp; \u0026nbsp; \u0026nbsp;Needs assessment\u003c/p\u003e\n\u003cp\u003eConsidering the epidemiological scenario, new solutions on the market must emphasize maximizing health outcomes for patients. Early, intensive, coordinated and continuous dialogue among all PM stakeholders is needed to foster process optimization and accelerate the acquisition of new technologies and tools.\u003c/p\u003e\n\u003cp\u003ec.\u0026nbsp; \u0026nbsp; \u0026nbsp;Principles and guidelines\u003c/p\u003e\n\u003cp\u003eThe PM actors should follow shared principles and universal data sharing and exchange guidelines. Innovations that aim for higher therapeutic value should be rewarded. Social value assessment should be systematically applied.\u003c/p\u003e\n\u003cp\u003ed.\u0026nbsp; \u0026nbsp; \u0026nbsp;Perspectives\u003c/p\u003e\n\u003cp\u003eStakeholders stimulating innovation should take a holistic and long-term perspective on the balance sheet. The interconnection and mutual dependence between diagnostic and therapeutic innovations and the potential for inappropriate use/ overuse must be taken into account.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eII-Adopting Big Data and ICT solutions\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003ea.\u0026nbsp; \u0026nbsp; \u0026nbsp;Data exchange\u003c/p\u003e\n\u003cp\u003eTo promote PM, Big Data must be analysable, comparable and interoperable across borders. The need emerges to carefully identify the type of information to be retained, increasingly favouring those related to health outcomes rather than information with no proven clinical or management value. To facilitate data exchange procedures, greater cooperation between academia, healthcare systems (including providers and payers), and industry would be advisable.\u003c/p\u003e\n\u003cp\u003eb.\u0026nbsp; \u0026nbsp; \u0026nbsp;Privacy, security, and trust\u003c/p\u003e\n\u003cp\u003eData security measures are a priority in developing new ICT solutions, which are crucial at the global level and not only focusing on high-income countries. Social and cultural differences between Europe and China should also be considered when it comes to public trust in government and state authorities, trying to reach a common understanding of shared challenges within PM. Involving the public can enhance awareness about data sharing benefits, its extended purposes, anonymization, privacy risks, security, private sector involvement, personal data protection, and foster frameworks aligned with societal agreement.\u003c/p\u003e\n\u003cp\u003ec. \u0026nbsp; \u0026nbsp; Standards\u003c/p\u003e\n\u003cp\u003eIn the PM field, it is essential to study solutions aimed at effectively combining data from different sources (genetics, clinical data) and regions, focusing on their standardization for effective usage. Standards for data use should be adopted and implemented, also with a view to establishing common policies and global efforts for cross-border data sharing.\u003c/p\u003e\n\u003cp\u003e\u003cu\u003ePillar 3: Research and clinical studies in PM\u003c/u\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eI-Fostering research funding\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003ea.\u0026nbsp; \u0026nbsp; \u0026nbsp;Patient needs\u003c/p\u003e\n\u003cp\u003eFunding agencies should tailor investments to the needs of patients. There is a need to promote the voice of patients (and caregivers) at all stages of PM research, from co-designing research projects to advisory roles and enhancing educational initiatives to improve the scientific literacy of patients and researchers. Defining unmet needs and potential incremental innovation could help in laying the groundwork for new international collaborations.\u003c/p\u003e\n\u003cp\u003eb.\u0026nbsp; \u0026nbsp; \u0026nbsp;Value chain\u003c/p\u003e\n\u003cp\u003eInvestments, playing an important role in the entire value chain, are needed from basic science to implementing PM in healthcare. Funders, both public and private, act as the first filter on the prioritization of resource allocation which should be done responsibly. Furthermore, adequate investments are crucial in the research translation system.\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003ec.\u0026nbsp; \u0026nbsp; \u0026nbsp;Synergies\u003c/p\u003e\n\u003cp\u003eEstablishing synergies between funders and the research community is the first step in implementing PM as a community. Implementing the exchange of researchers through mobility funding programs could promote collaboration and knowledge sharing between different countries and foster data sharing. Collaborations between funders should be established to align on research themes and fund larger, bold, cutting-edge projects that enable risk sharing.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eII-Translating basic clinical research and beyond\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003ed.\u0026nbsp; \u0026nbsp; \u0026nbsp;Omics sciences\u003c/p\u003e\n\u003cp\u003eOmics sciences are fundamental to the development of PM. Phenotyping patients, following defined standards, could identify similar patients. Besides genomics, applications of different omics sciences and technologies should be promoted and used to identify biomarkers suitable for PM. Innovative methods that have shown great promise in the PM field, including induced pluripotent stem cell and organ-on-chips models, should be evaluated and adopted, valuing international partnerships.\u003c/p\u003e\n\u003cp\u003ee.\u0026nbsp; \u0026nbsp; \u0026nbsp;Data and standards\u003c/p\u003e\n\u003cp\u003eStandardizing approaches, including controlled access models for data sharing and clinical trials, may facilitate their implementation and help in patient stratification. Patient stratification in non-genetic/complex diseases would benefit from research programs on machine learning algorithms. Furthermore, using specific use cases could help in the development of common international standards and tools for research. Exchanges and dialogue between regulatory agencies should be promoted to overcome regulatory problems in PM, particularly on benefit-risk relationships.\u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp; \u0026nbsp;\u003c/p\u003e\n\u003cp\u003ef.\u0026nbsp; \u0026nbsp; \u0026nbsp;Collaborations\u003c/p\u003e\n\u003cp\u003eIt is important to support non-profit foundations and funding agencies to promote international collaborations, especially in oncological care and rare diseases. Establishing specific funding programmes and operational frameworks for public-private collaboration can facilitate academic and industrial access to biological samples and data for research purposes. It is necessary to facilitate and strengthen the dialogue with regulatory and HTA agencies, companies, and academic entities to gain a clear vision regarding outcomes researched and identify the most appropriate research methods to investigate PM, ensuring patient safety and adapting to the characteristics of study populations.\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eThe IC2PerMed roadmap illustrates strategic actions aimed at fostering international collaboration between China and the EU in the PM realm. These actions are intended to facilitate collaborative initiatives and enhance the optimization of research and developments, using the three pillars feeding the working groups\u0026rsquo; activities as cornerstones.\u003c/p\u003e \u003cp\u003eCloser cooperation between the two sides can lead to synergies and gains for both. The alignment of research efforts and promotion of common research initiatives in science and technology could lead to reduction of redundancies and improved use of available monetary, technological and human resources. Generating substantial evidence can often be challenging due to limited data availability. This is particularly frequent for patients affected by some conditions, or undergoing personalized interventions, that might not generate enough data. Partnerships between institutions working in the same field can facilitate the collation of available evidence by pooling available data. On the other hand, collaborations between diverse entities can lead to reciprocal benefits, e.g. feedback on data reproducibility to basic research institutions while enabling translational institutions to gain insights and preliminary findings from closer collaborations. In this context, clusters that bring together different entities and foster cross-field cooperation play a crucial role in facilitating such joint efforts. The current high fragmentation of the sector calls for concerted efforts towards integration under common guidelines.\u003c/p\u003e \u003cp\u003eEngaging with all stakeholders is essential to incorporate diverse perspectives and ensure effective policy development. The IC2PerMed roadmap could orientate the efforts of policymakers, industry, healthcare professionals and citizens.\u003c/p\u003e \u003cp\u003ePolicymakers often struggle to keep up with innovation, especially in high-transformative fields like PM. Policymakers play a central role as the primary recipients of countries' assistance and research priorities, wielding significant influence in the formulation and implementation of healthcare policies. The regulatory landscape is heterogeneous and fragmented in the EU and China, often relying on ad-hoc initiatives and projects [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]. The speed at which innovation proceeds is often incompatible with the times of policymaking, leaving much room for the introduction of unregulated technologies into practice, sometimes with negative effects [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]. In healthcare, normative gaps can expose people\u0026rsquo;s health and well-being to unanticipated risks. Therefore, emerging technologies and processes should be carefully evaluated before they are adopted [\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e]. Significant issues can arise, possibly related to the unintended effects of adopting some technology or concerning the data generated by it. If not stored safely and anonymously, data leakages or hacker attacks can lead to data theft, with several unwanted consequences that are particularly negative in the case of genomic data [\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eFacilitating the exchange of health data among different institutions, even from different countries, is a priority in the EU, that is working for the creation of the European Health Data Space to address health-specific challenges to electronic health data access and sharing, focusing on interoperability and cross-border sharing. More federated data infrastructures (as fostered by the 1\u0026thinsp;+\u0026thinsp;Million Genomes Initiative, which has led to the Beyond 1\u0026thinsp;+\u0026thinsp;Million Genomes and the Genomic Data Infrastructure projects) will also contribute to this goal [\u003cspan additionalcitationids=\"CR26 CR27 CR28\" citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eBig Data raises several issues, including personal data ownership and protection, skill gaps in labour markets and an emerging new digital divide [\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e]. Hence, policies in this field are fundamental for regulating these aspects [\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e]. Regarding data protection, notable distinctions exist between Europe and China.\u003c/p\u003e \u003cp\u003eEurope\u0026rsquo;s regulation on data, the General Data Protection Regulation (GDPR), places significant emphasis on obtaining explicit consent or relying on legal exemptions for utilizing health data. In cross-border collaborations with third countries, such as China, data transfers necessitate adherence to the same level of data protection as enforced in the EU [\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e]. Conversely, China has implemented a comprehensive data protection framework, encompassing laws such as the Data Security Law, Cybersecurity Law, and Personal Information Protection Law [\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e]. These regulations are primarily oriented toward national security, public interest, and safeguarding fundamental data. Moreover, China has specific regulations, such as the Measures for Managing Scientific Data, governing the transfer of scientific data to designated data centres. These measures ensure the confidentiality and security of data, with a particular focus on prohibiting the disclosure of sensitive information [\u003cspan additionalcitationids=\"CR34\" citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThe contrasting approaches between the two parts in data protection stem from their respective regulatory frameworks, varying consent requirements, and targeted legislation addressing different aspects of data protection and governance and promoting partnerships to facilitate data sharing and the creation of collaborative datasets [\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e, \u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eHowever, new solutions and advanced technologies, even if promising better outcomes for patients, can come at a high cost, hindering the implementation process and healthcare systems\u0026rsquo; sustainability [\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e, \u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e]. Some solutions have been proposed, from checklists and instruments to measure PM solutions\u0026rsquo; utility to performing economic evaluations that would ensure an intervention\u0026rsquo;s cost-effectiveness, like HTA and Health Impact Assessment (HIA) [\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e, \u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e]. Nonetheless, need-assessment and integration of end-users\u0026rsquo; perspectives seem to be neglected.\u003c/p\u003e \u003cp\u003eFor PM to reach its impact on patients\u0026rsquo; health and well-being, translation of discoveries and communication across the continuum of research is required [\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e]. The development of preclinical and clinical model of disease benefits from the integration of \u0026lsquo;-omics\u0026rsquo; data, useful to define molecular profiles. [\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e]. In order to standardize the process, identify biomarkers and correctly collect data, international consensus should be reached [\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e]. Developing new clinical trial designs including these innovative instruments and approaches contribute to the outcome research and the evaluation of interventions [\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e]. Cross-sectional research and collaboration should be supported by suitable funding mechanisms, valuing the existing instruments or promoting the establishment of new ones [\u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e]. As per the mapping of major funding agencies and stakeholders in Europe and China in IC2PerMed\u0026rsquo;s deliverable D1.2, great similarities can be found in the structure of funding mechanisms and areas of interest [\u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eConcerning industry and universities, which are the main actors in PM research and innovation in the EU and China [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e], the results refer to the importance of investments of translating research into the market and partnerships between industrial partners and academia. Collaborations hold large economic potential, where global leaders can extend their reach and value chains to new markets. Both parties should pursue partnerships, collaborations and workshops to communicate and interact. Nonetheless, bridging the translational gap is crucial, and ensuring that universities and industries communicate will help address issues such as the skills mismatch [\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e, \u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eTo implement PM in clinical and public health practice, both patients and health professionals should be aware of the possibilities offered and how to make the most of them [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e, \u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]. Given the need for informed, empowered, engaged and responsible citizens, there is a need to deepen digital literacy, knowledge of health data, public trust in institutions and easily accessible, reliable and understandable sources of medical information. Informed, accountable and empowered health service providers are also essential. Establish a normative framework for the exploitation of health information and research results in PM should be implemented for clinical practices [\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e]. Multidisciplinary collaborations improve the involvement of citizens in decision-making, promoting the creation of advocacy groups to represent the needs and perspectives of citizens and patients with policymakers [\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e]. Patients/citizens advocacy groups should collaborate with healthcare professionals and policymakers to improve health literacy and involvement in research, as well as to identify citizens' needs and sources of lack of trust [\u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e]. It should be noted that the bilateral efforts on standardization in PM will benefit the whole field and allow health challenges to be tackled globally in a concerted manner.\u003c/p\u003e \u003cp\u003eThe results of this work should be considered in light of some strengths and limitations. To the authors\u0026rsquo; knowledge, this is the first attempt to present a comprehensive roadmap addressing multiple issues in the field of PM, with a specific focus on the collaboration with China. This document offers a tool for policymakers, highlighting emerging issues and experts\u0026rsquo; considerations in the field. In addition, this roadmap includes other relevant stakeholders in the field of PM, adding value to its content.\u003c/p\u003e \u003cp\u003eThe methodology used, particularly careful to intertwine the scientific literature, institutional sources and the opinion of experts, led to building a roadmap where each step was carefully evaluated and validated. This helped guarantee the quality and reliability of the results. In addition, the roadmap provides indications on aspects of PM that want to be as comprehensive as possible of the current scenario and challenges. However, arising from the international comparison of two realities, the European and the Chinese, which do not completely overlap in culture, political strategies, health systems, and technological advancement, it is possible that some aspects sound less specific compared to others. Furthermore, it is possible that some aspects relevant to PM have been neglected because of the adoption of as \u0026ldquo;perspectives\u0026rdquo; identified in the ICPerMed Vision for 2030.\u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003ePM has the potential to disrupt the medical field bringing major improvements for the benefit of public health. In doing so, PM affects citizens, patients, their families, and communities, at all levels of the entire healthcare system.\u003c/p\u003e \u003cp\u003eThe development of PM requires concise action across universities, industrial partners, and national governments and urges for synchronous development on a global scale. To do so, the alignment of European and Chinese efforts, finding common ground across cultural, social, and language barriers can enhance public health efforts in applying PM strategies internationally.\u003c/p\u003e \u003cp\u003eAlthough different countries may have different perspectives because the specific national agenda may differ, PM acts as a collector of converging interests by acknowledging the best care for citizens and patients at its centre. The IC2PerMed roadmap represents an instrument for PM implementation, tackling the modern challenges of medicine and healthcare pragmatically in a list of doable actions. Implementing PM in a transversal way and welcoming new discoveries while considering sustainability holds the potential to have a revolutionary impact on healthcare, but this will require a concerted effort.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003eEthics Approval Statement: This study does not involve human participants and ethical approval was not required.\u003c/p\u003e\n\u003cp\u003eAvailability of data and materials: Not applicable\u003c/p\u003e\n\u003cp\u003eConflict of Interest statement: None to declare.\u003c/p\u003e\n\u003cp\u003eContributore: Sara Farina\u003csup\u003e1\u003c/sup\u003e, Cosimo Savoia\u003csup\u003e1\u003c/sup\u003e, Tommaso Osti\u003csup\u003e1\u003c/sup\u003e, Benoit Masquin\u003csup\u003e4\u003c/sup\u003e, Svetlana Klessova\u003csup\u003e4\u003c/sup\u003e, Timo Stroh\u0026auml;ker\u003csup\u003e6\u003c/sup\u003e, Giuditta Magnifico\u003csup\u003e7\u003c/sup\u003e, Stefano Benvenuti\u003csup\u003e7\u003c/sup\u003e, Andrea Wutte\u003csup\u003e8\u003c/sup\u003e, Bettina Borisch\u003csup\u003e9\u003c/sup\u003e, Maria Mata\u003csup\u003e9\u003c/sup\u003e\u003c/p\u003e\n\u003cp\u003eAuthor Contributions: FB, FAC and MDM were major contributors to the drafting of the manuscript. \u0026nbsp;All the other authors made important contributions and suggestions. WR and SB revised the manuscript substantially. All authors read and approved the final manuscript.\u003c/p\u003e\n\u003cp\u003eFundings: This work was supported by the European Union\u0026rsquo;s Horizon 2020 research and innovation programme [grant numbers 87469]; the National Key R\u0026amp;D Program of Ministry of Science and Technology of the People\u0026apos;s Republic of China (MOST) [grant number 2021YFE019240].\u003c/p\u003e\n\u003cp\u003eThe authors wish to express their sincere gratitude to all the experts who took part in the project for their valuable contributions to this study.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eO\u0026rsquo;Donnell JC. Personalized medicine and the role of health economics and outcomes research: issues, applications, emerging trends, and future research. Value Health J Int Soc Pharmacoeconomics Outcomes Res 2013; 16: S1-3.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCollins F. Has the revolution arrived? Nature 2010; 464: 674\u0026ndash;675.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFosse V, Oldoni E, Bietrix F, et al. Recommendations for robust and reproducible preclinical research in personalised medicine. BMC Med 2023; 21: 14.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTraversi D, Pulliero A, Izzotti A, et al. Precision Medicine and Public Health: New Challenges for Effective and Sustainable Health. J Pers Med 2021; 11: 135.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePersonalised medicine, \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://research-and-innovation.ec.europa.eu/research-area/health/personalised-medicine_en\u003c/span\u003e\u003cspan address=\"https://research-and-innovation.ec.europa.eu/research-area/health/personalised-medicine_en\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2023, accessed 24 July 2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eStenzinger A, Moltzen EK, Winkler E, et al. Implementation of precision medicine in healthcare - a European perspective. \u003cem\u003eJ Intern Med\u003c/em\u003e. Epub ahead of print 16 July 2023. DOI: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/joim.13698\u003c/span\u003e\u003cspan address=\"10.1111/joim.13698\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTinetti ME, Fried T. The end of the disease era. Am J Med 2004; 116: 179\u0026ndash;185.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMorsella A, Cadeddu C, Castagna C, et al. \u0026lsquo;Integrating China in the International Consortium for Personalized Medicine\u0026rsquo;: The Coordination and Support Action to Foster Collaboration in Personalized Medicine Development between Europe and China. Public Health Genomics 2021; 24: 310\u0026ndash;314.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBeccia F, Hoxhaj I, Castagna C, et al. An overview of Personalized Medicine landscape and policies in the European Union. Eur J Public Health 2022; 32: 844\u0026ndash;851.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHoxhaj I, Beccia F, Morsella A, et al. A survey of experts on personalized medicine landscape in European Union and China. BMC Health Serv Res 2023; 23: 517.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003e中共中央 国务院印发《\u0026ldquo;健康中国2030\u0026rdquo;规划纲要》_中央有关文件_中国政府网, \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.gov.cn/zhengce/2016-10/25/content_5124174.htm\u003c/span\u003e\u003cspan address=\"https://www.gov.cn/zhengce/2016-10/25/content_5124174.htm\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (accessed 24 July 2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003e中华人民共和国国民经济和社会发展第十四个五年规划和2035年远景目标纲要_滚动新闻_中国政府网, \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.gov.cn/xinwen/2021-03/13/content_5592681.htm\u003c/span\u003e\u003cspan address=\"https://www.gov.cn/xinwen/2021-03/13/content_5592681.htm\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (accessed 24 July 2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVicente AM, Ballensiefen W, J\u0026ouml;nsson J-I. How personalised medicine will transform healthcare by 2030: the ICPerMed vision. J Transl Med 2020; 18: 180.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eIC2PERMED: Fostering collaboration between Europe and China to enhance personalised medicine. Open Access Government, \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.openaccessgovernment.org/article/ic2permed-europe-china-to-enhance-personalised-medicine/160981/\u003c/span\u003e\u003cspan address=\"https://www.openaccessgovernment.org/article/ic2permed-europe-china-to-enhance-personalised-medicine/160981/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2023, accessed 24 July 2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePublications \u0026amp; public deliverables \u0026ndash; IC2PerMed, \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.ic2permed.eu/publications-public-deliverables-2/\u003c/span\u003e\u003cspan address=\"https://www.ic2permed.eu/publications-public-deliverables-2/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (accessed 17 March 2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCausio FA, Hoxhaj I, Beccia F, et al. Big data and ICT solutions in the European Union and in China: A comparative analysis of policies in personalized medicine. Digit Health 2022; 8: 20552076221129060.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCausio FA, Hoxhaj I, Beccia F, et al. Research and innovation in personalized medicine: a descriptive synthesis of actors in the EU and China. \u003cem\u003ePers Med\u003c/em\u003e. Epub ahead of print 17 May 2023. DOI: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.2217/pme-2023-0003\u003c/span\u003e\u003cspan address=\"10.2217/pme-2023-0003\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRomain. Project news. \u003cem\u003eIC2PerMed\u003c/em\u003e, \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.ic2permed.eu/news/\u003c/span\u003e\u003cspan address=\"https://www.ic2permed.eu/news/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (accessed 11 October 2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBeccia F, Causio FA, Hoxhaj I, et al. Integrating China in the international consortium for personalised medicine. a position paper on healthcare professionals\u0026rsquo; education and citizens\u0026rsquo; empowerment in personalised medicine. BMC Med Educ 2023; 23: 438.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eIntegrating China in the International Consortium for Personalised Medicine. A Position Paper on Research, Clinical Studies and Funding Systems in Personalised Medicine.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eIntegrating China in the International Consortium for Personalised Medicine. A Position Paper on Innovation and Digitalization in Personalised Medicine.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eIntegrating China in the International Consortium for Personalised Medicine. A position Paper on Personalised Medicine in Sustainable Healthcare.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCallier S, Fullerton SM. Diversity and Inclusion in Unregulated mHealth Research: Addressing the Risks. J Law Med Ethics J Am Soc Law Med Ethics 2020; 48: 115\u0026ndash;121.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eOestreich M, Chen D, Schultze JL, et al. Privacy considerations for sharing genomics data. EXCLI J 2021; 20: 1243\u0026ndash;1260.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEuropean Genomic Data Infrastructure (GDI) project, \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://gdi.onemilliongenomes.eu/\u003c/span\u003e\u003cspan address=\"https://gdi.onemilliongenomes.eu/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (accessed 24 July 2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBeyond One Million Genomes (B1MG) project, \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://b1mg-project.eu/\u003c/span\u003e\u003cspan address=\"https://b1mg-project.eu/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (accessed 24 July 2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEU AI Act: first regulation on artificial intelligence | News | European Parliament, \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.europarl.europa.eu/news/en/headlines/society/20230601STO93804/eu-ai-act-first-regulation-on-artificial-intelligence\u003c/span\u003e\u003cspan address=\"https://www.europarl.europa.eu/news/en/headlines/society/20230601STO93804/eu-ai-act-first-regulation-on-artificial-intelligence\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2023, accessed 24 July 2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMinssen T, Vayena E, Cohen IG. The Challenges for Regulating Medical Use of ChatGPT and Other Large Language Models. \u003cem\u003eJAMA\u003c/em\u003e. Epub ahead of print 6 July 2023. DOI: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1001/jama.2023.9651\u003c/span\u003e\u003cspan address=\"10.1001/jama.2023.9651\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEuropean Health Data Space, \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://health.ec.europa.eu/ehealth-digital-health-and-care/european-health-data-space_en\u003c/span\u003e\u003cspan address=\"https://health.ec.europa.eu/ehealth-digital-health-and-care/european-health-data-space_en\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (2023, accessed 25 July 2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePastorino R, De Vito C, Migliara G, et al. Benefits and challenges of Big Data in healthcare: an overview of the European initiatives. Eur J Public Health 2019; 29: 23\u0026ndash;27.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWhat is GDPR, the EU\u0026rsquo;s new data protection law? \u003cem\u003eGDPR.eu\u003c/em\u003e, \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://gdpr.eu/what-is-gdpr\u003c/span\u003e\u003cspan address=\"https://gdpr.eu/what-is-gdpr\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e/ (2018, accessed 24 July 2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTranslation: Cybersecurity Law of the People\u0026rsquo;s Republic of China (Effective June 1, 2017). \u003cem\u003eDigiChina\u003c/em\u003e, \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://digichina.stanford.edu/work/translation-cybersecurity-law-of-the-peoples-republic-of-china-effective-june-1-2017/\u003c/span\u003e\u003cspan address=\"https://digichina.stanford.edu/work/translation-cybersecurity-law-of-the-peoples-republic-of-china-effective-june-1-2017/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e (accessed 24 July 2023).\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhang L, Wang H, Li Q, et al. Big data and medical research in China. BMJ 2018; 360: j5910.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhang L, Downs RR, Li J, et al. A Review of Open Research Data Policies and Practices in China. 2021; 20: 3.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHuang Y, Cox AM, Sbaffi L. Research data management policy and practice in Chinese university libraries. J Assoc Inf Sci Technol 2021; 72: 493\u0026ndash;506.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTrottet C, Vogels T, Keitel K, et al. Modular Clinical Decision Support Networks (MoDN)-Updatable, interpretable, and portable predictions for evolving clinical environments. PLOS Digit Health 2023; 2: e0000108.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJ\u0026ouml;nsson B, Hofmarcher T, Lindgren P, et al. The cost and burden of cancer in the European Union 1995\u0026ndash;2014. Eur J Cancer Oxf Engl 1990 2016; 66: 162\u0026ndash;170.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePastorino R, Loreti C, Giovannini S, et al. Challenges of Prevention for a Sustainable Personalized Medicine. J Pers Med 2021; 11: 311.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003evan Rooij T, Wilson DM, Marsh S. Personalized medicine policy challenges: measuring clinical utility at point of care. Expert Rev Pharmacoecon Outcomes Res 2012; 12: 289\u0026ndash;295.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFerrusi IL, Leighl NB, Kulin NA, et al. Do economic evaluations of targeted therapy provide support for decision makers? \u003cem\u003eAm J Manag Care\u003c/em\u003e 2011; 17 Suppl 5 Developing: SP61-70.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEquils O, Bakaj A, Wilson-Mifsud B, et al. Restoring Trust: The Need for Precision Medicine in Infectious Diseases, Public Health and Vaccines. Hum Vaccines Immunother 2023; 19: 2234787.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMoutinho S. Clinical trials assess a precision-medicine approach to cancer screening. Nat Med 2023; 29: 1587\u0026ndash;1590.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRomagnuolo I, Mariut C, Mazzoni A, et al. Sino-European science and technology collaboration on personalized medicine: overview, trends and future perspectives. Pers Med 2021; 18: 455\u0026ndash;470.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eStrohaeker T. D1.2 Map of major funding agencies and stakeholders in Europe and China.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePeng J, Deng C. Research on the relationship between college students\u0026rsquo; employability and IT skills training based on mixed research methods. Front Psychol 2022; 13: 1054134.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCooke J, Ariss S, Smith C, et al. On-going collaborative priority-setting for research activity: a method of capacity building to reduce the research-practice translational gap. Health Res Policy Syst 2015; 13: 25.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRasooly A, Ben-Sheleg E, Davidovitch N, et al. Rethinking the path from evidence to decision-making. Isr J Health Policy Res 2023; 12: 10.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNeubeck L, Galbraith M, Drossart I, et al. The essential role of patients in advocacy and policy. Eur Heart J 2023; 44: 2506\u0026ndash;2507.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Personalized medicine, Roadmap, China, European Union, Priorities","lastPublishedDoi":"10.21203/rs.3.rs-4643972/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4643972/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003ePersonalized medicine (PM) tailors prevention and treatment to individuals based on their unique characteristics. It can improve health outcomes and healthcare sustainability by optimizing resource allocation. The European Union (EU) and China both prioritize PM. The IC2PerMed project aims to facilitate collaboration by developing a PM roadmap.\u003c/p\u003e \u003cp\u003eThis paper presents the main project\u0026rsquo;s output, a roadmap for implementing PM in the EU and China, promoting best practice exchange, and addressing potential barriers.\u003c/p\u003e \u003cp\u003eWe assessed PM in the EU and China by mapping policies, programs, funding mechanisms, and health ecosystems. Three Delphi surveys highlighted 65 priorities, which were synthesized into actions.\u003c/p\u003e \u003cp\u003eThe study identifies priorities to unlock PM's potential for healthcare transformation and better public health. The roadmap includes structural actions, like enhancing health literacy, fostering intersectoral and international collaboration, continuously reviewing technologies, and facilitating innovation market entry through needs assessment and Health Technology Assessment. Data interoperability and shared standards are critical for creating international platforms, and ethical, social, and regulatory considerations are universal in PM processes.\u003c/p\u003e \u003cp\u003eA shared action plan can guide health policy and help policymakers understand the interconnection between healthcare, the economy, and society. By supporting international projects and investing in research and innovation, stakeholders can advance global healthcare.\u003c/p\u003e","manuscriptTitle":"A Roadmap for Personalized Medicine: the findings of the IC2PerMed Project ","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-08-09 14:33:56","doi":"10.21203/rs.3.rs-4643972/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"fa3a2e49-ee21-4e0d-bc03-6d8f38e60347","owner":[],"postedDate":"August 9th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2025-03-05T20:08:20+00:00","versionOfRecord":[],"versionCreatedAt":"2024-08-09 14:33:56","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-4643972","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4643972","identity":"rs-4643972","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}